Category: Top Story

Olema Pharmaceuticals (NASDAQ:OLMA) plunged 28% in premarket trading Monday after releasing data from an early- to mid-stage breast cancer study that was overshadowed by disappointing results from Roche. Matthew Biegler, analyst at Oppenheimer, noted that Olema’s “stellar” combination therapy data risk being eclipsed by Roche’s breast cancer trial outcome, “which missed the buy-side’s mark.” Roche’s…

Sable Offshore Corp. (NYSE:SOC) saw its stock jump 15% in premarket trading Monday after Chris Wright, the U.S. Energy Secretary, publicly voiced support for the company’s long-delayed oil project off the California coast. On Friday night, Wright took to X (formerly Twitter) to criticize state officials for stalling the approval process. “Only in California! Newsom…

Replimune Group Inc (NASDAQ:REPL) surged 60% in premarket trading after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of its Biologics License Application (BLA) for RP1, a treatment for advanced melanoma. The application seeks approval for RP1 in combination with nivolumab to treat patients with advanced melanoma who have progressed on anti-PD-1–based…

Investar Holding Corporation (NASDAQ:ISTR), parent company of Investar Bank, reported stronger-than-expected third-quarter earnings on Monday, boosted by improved net interest margin and steady loan growth. The Louisiana-based lender posted adjusted earnings of $0.54 per share, beating analyst forecasts of $0.46. Revenue came in at $24.14 million, ahead of the $22.5 million consensus estimate. Net income…

Summit Therapeutics (NASDAQ:SMMT) saw its stock decline 3.53% in premarket trading Monday following the release of its third-quarter earnings. The company posted a non-GAAP net loss of $0.13 per share, beating analyst expectations of a $0.17 loss. Operating expenses jumped to $103.4 million on a non-GAAP basis from $39.0 million in the same period last…

Exelixis (NASDAQ:EXEL) saw its stock tumble 9.1% in premarket trading Monday after unveiling results from two separate late-stage studies evaluating its cancer therapies. In one update, the company reported data from a trial assessing its experimental treatment for colorectal cancer, which combines zanzalintinib with atezolizumab (marketed as Tecentriq) compared to regorafenib. After a median follow-up…

Boeing (NYSE:BA) shares rose 1.7% in premarket trading on Monday after the Federal Aviation Administration (FAA) approved a production rate increase for the company’s 737 MAX aircraft. The regulator gave Boeing the go-ahead to lift monthly output from 38 to 42 aircraft, a move that aligns with analyst projections that the company would hit this…

Cleveland-Cliffs Inc. (NYSE:CLF) posted a third-quarter adjusted loss of $0.45 per share on Monday, matching analyst forecasts, while revenue reached $4.7 billion, just shy of the expected $4.9 billion. The stock edged up 0.30% in premarket trading as investors responded to encouraging signs of a rebound in automotive steel demand. Third-quarter steel shipments climbed to…

Investors head into the week with eyes fixed on signs of a potential cooling of tensions between the U.S. and China, as high-level meetings could take place before the end of the month. Alongside trade developments, a busy stretch of corporate earnings and the release of delayed U.S. inflation data will shape sentiment in the…

U.S. equities closed out last week on a high note, supported by renewed optimism over U.S.–China trade discussions and fading concerns from the regional bank selloff earlier in the week. The Dow Jones Industrial Average gained 238.37 points, or 0.52%, to end at 46,190.61, while the S&P 500 added 0.53% to finish at 6,664.01. The…